Surveillance of injectable antimicrobial consumption was conducted at 55 institutes to elucidate the relationship between carbapenem consumption and imipenem or meropenem-resistant rates in
Pseudomonas aeruginosa in the Tokai region using the Anatomical Therapeutic Chemical classification/Defined Daily Dose system. The consumption of antimicrobial agents (13.7 DDDs/100 bed days) in 2008 significantly increased compared to that (12.8 DDDs/100 bed days) in 2007 (p=0.010). In particular, cephalosporin consumption (from 5.3 DDDs/100 bed days to 5.6 DDDs/100 bed days, p=0.028) and glycopeptide consumption (from 0.4 DDDs/100 bed days to 0.5 DDDs/100 bed days, p=0.009) significantly increased. On the other hand, carbapenem consumption (1.3 DDDs/100 bed days) in 2008 was comparable to that (1.2 DDDs/100 bed days) in 2007 (p=0.418). These results are useful as an index for comparing intergroup and nationwide antimicrobial consumption. No relationship was found between the consumption of carbapenem and imipenem or meropenem-resistant rates in
P. aeruginosa. Since the consumption of carbapenem seems to exert little influence on the resistance of
P. aeruginosa, some factors other than carbapenem consumption should be considered.
View full abstract